| Kristi Chioni, | |
|
2203 Eastland Dr, Bloomington, IL 61704-7918 | |
| (800) 444-6110 | |
| Not Available |
| Full Name | Kristi Chioni |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 2203 Eastland Dr, Bloomington, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093118127 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 041336362 (Illinois) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 209011877 (Illinois) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Guardian Headache And Pain Management Institute Llc | 1153504956 | 3 |
News Archive
People who experience childhood maltreatment frequently have perturbations in their brain architecture, regardless of whether they develop psychiatric symptoms, but a study in Biological Psychiatry found additional alterations in people who don't develop symptoms.
Drinking 100 percent fruit juices could have protective health benefits similar to those of whole fruits, according to research presented in a literature review yesterday at the 2011 Experimental Biology meeting.
The concept is simple: to halt deterioration of the heart muscle, wrap it in a mesh-like net to prevent further enlargement in patients with heart failure. It's like a jacket for the heart.
Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery.
› Verified 7 days ago
| Entity Name | Guardian Headache & Pain Management Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912202409 PECOS PAC ID: 1153504956 Enrollment ID: O20110331000174 |
News Archive
People who experience childhood maltreatment frequently have perturbations in their brain architecture, regardless of whether they develop psychiatric symptoms, but a study in Biological Psychiatry found additional alterations in people who don't develop symptoms.
Drinking 100 percent fruit juices could have protective health benefits similar to those of whole fruits, according to research presented in a literature review yesterday at the 2011 Experimental Biology meeting.
The concept is simple: to halt deterioration of the heart muscle, wrap it in a mesh-like net to prevent further enlargement in patients with heart failure. It's like a jacket for the heart.
Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristi Chioni, 2203 Eastland Dr, Bloomington, IL 61704-7918 Ph: (800) 444-6110 | Kristi Chioni, 2203 Eastland Dr, Bloomington, IL 61704-7918 Ph: (800) 444-6110 |
News Archive
People who experience childhood maltreatment frequently have perturbations in their brain architecture, regardless of whether they develop psychiatric symptoms, but a study in Biological Psychiatry found additional alterations in people who don't develop symptoms.
Drinking 100 percent fruit juices could have protective health benefits similar to those of whole fruits, according to research presented in a literature review yesterday at the 2011 Experimental Biology meeting.
The concept is simple: to halt deterioration of the heart muscle, wrap it in a mesh-like net to prevent further enlargement in patients with heart failure. It's like a jacket for the heart.
Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery.
› Verified 7 days ago